Editorial

Rakuten Medical is Developing ASP-1929 photoimmunotherapy Based on the Alluminox® Platform as a Selective Cancer Treatment with Focused Local Control

TROP-2 and the Promise and Peril of High-Affinity in ADCs -- Over the last decades, Antibody–drug conjugates (ADCs) have emerged as a transformative class of cancer therapeutics, offering the promise of targeted cytotoxicity with the precision of monoclonal antibodies.* To fulfill this promise, the ideal ADC includes an antibody that is specific for binding to the target antigen, has high binding affinity for that target, and, at the same time, has low immunogenicity.  In addition, the antibody should have a long plasma half-life and rapid internalization.

Antibody-Drug Conjugates in Gastric Cancer: Clinical Progress, Resistance, and the Road Ahead

Engineering the Future of Cancer Care: How Next-Generation Antibody-Drug Conjugates (ADCs) Are Shaping Oncology and Beyond

Reviewing the Key Trends and Insights from the ADC Linker & Conjugation Summit

The Opportunity to go Beyond “chemo on a stick” ADCs

Finding Synergies in Combining ADCs with Multispecific Antibodies

Required adaptations to clinical trial design and execution, implemented during the COVID-19 pandemic, have put a new focus on the development of patient-focused, decentralized...

Biologics are changing the way we treat disease, affecting where companies invest, and, most importantly, impacting patients’ lives. Last year, nearly half of the 37 new drugs approved by the U.S. Center for Drug Evaluation and Research (CDER) were biologics, while its partner agency—the U.S. [1] Center for Biologics Evaluation and Research (CBER)—approved a dozen additional products. [2] These approvals span many modalities and cover a range of conditions, including many rare and hard-to-treat diseases.

For some time now, cancer drug developers have known “Project Optimus” and new dose optimization expectations are coming their way from the Food and...